-
1 Comment
Hubei Biocause Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 17.2% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Hubei Biocause Pharmaceutical Co., Ltd's total revenue rose by 26.1% to $3B since the same quarter in the previous year.
Its net income has dropped by 79.4% to $55M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.7% to $4B since the same quarter in the previous year.
Based on the above factors, Hubei Biocause Pharmaceutical Co., Ltd gets an overall score of 3/5.
| ISIN | CNE000000F48 |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| Sector | Financial Services |
| Industry | Insurance - Life |
| Market Cap | 17B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.74 |
| Dividend Yield | None |
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000627.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
